Post-earnings recap
Reported
Fri, May 5, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which contributed to a slight increase in their stock price. The market reacted positively, likely due to management's focus on future clinical trials and ongoing projects. However, the lack of revenue details and guidance may leave investors cautious.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.25 | N/A | +0.30% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed optimism about their ongoing projects. They emphasized the significance of their research and development efforts.
Management highlighted progress in their pipeline despite the loss.
They noted the importance of upcoming clinical trials for future growth.